Leading US and European Medical Public-Private Partnerships Announce Agreement The Predictive Safety Testing Consortium (PSTC) led by the Critical Path Institute (C-Path) and the Safer and Faster Evidence-base
Opportunities and Challenges of Safety Biomarker Qualification: Perspectives from the Predictive Safety Testing Consortium
Tucson institute plays critical cancer role Re: the April 19 article “Vast study advances breast cancer fight.”
Critical Path Institute and Hamner Institutes for Health Sciences Announce Collaboration to Improve Safety of Medical Product Development Critical Path Institute(C-Path)and The Hamner Institutes for Health Sciences (The Hamner) announced today that they have signed a
February 8, 2011 Development and Evaluation of a Genomic Signature for the Prediction and Mechanistic Assessment of Nongenotoxic Hepatocarcinogens in the Rat
Critical Path Institute’s Predictive Safety Testing Consortium Announces First-Ever Qualification Decision by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). For the first time, new biomarker tests to detect drug-induced kidney injury have been accepted by the Japanese Pharmaceuticals an
Critical Path Institute’s Predictive Safety Testing Consortium Announces Special Issue of Nature Biotechnology Dedicated to Newly Qualified Kidney Safety Biomarkers A special May 10, 2010 issue of Nature Biotechnology (NBT) includes ten scientific publications from Critical Path Institute’
